Skip to page body Patient Care Survivorship Research Cancer Types News Giving Community Partners Clinical Trials
UCLA's Jonsson Comprehensive Cancer Center
Take the Jonsson Cancer Center Site Survey

JCCC Member Directory

Leonard S. Marks, M.D.
Leonard S. Marks, M.D.

Specialty:

Urology

General Information:

Gender:
Male
Language(s):
English

Affiliation(s):

Clinical Professor, Department of Urology
Member, JCCC Cancer Molecular Imaging Program Area

Hospital Affiliation(s):

Ronald Reagan UCLA Medical Center

Education:

Residency:
Urology, UCLA School of Medicine, 1974 - 1978
Surgery, Harbor - UCLA Medical Center, 1972 - 1973
Internship:
Surgery, Harbor - UCLA Medical Center, 1969 - 1970
Medical Degree:
M.D., University of Texas Medical Branch at Galveston, 1969

Certification(s):

Medical Board Certification(s):
Urology, American Board of Urology, 1980

Contact Information:

Phone:
(310) 794-3070
Email:

Practice Information:

Clinical Interest(s):
Prostate disease

Scientific Interest(s):

Dr. Leonard Marks' scientific interests include prostate imaging and targeted biopsy, minimally-invasive therapy for prostate cancer and testosterone replacement therapy.

Selected Cancer-Related Publications:

Catalona WJ, Partin AW, Sanda MG, Wei JT, Klee GG, Bangma CH, Slawin KM, Marks LS, Loeb S, Broyles DL, Shin SS, Cruz AB, Chan DW, Sokoll LJ, Roberts WL, van Schaik RH, Mizrahi IA. A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol. 2011 May;185(5):1650-5. Epub 2011 Mar 17

Natarajan S, Marks LS, Margolis DJ, Huang J, Macairan ML, Lieu P, Fenster A. Clinical application of a 3D ultrasound-guided prostate biopsy system. Urol Oncol. 2011 May-Jun;29(3):334-42.

Xie C, Kim HJ, Haw JG, Kalbasi A, Gardner BK, Li G, Rao J, Chia D, Liong M, Punzalan RR, Marks LS, Pantuck AJ, de la Taille A, Wang G, Mukouyama H, Zeng G. A novel multiplex assay combining autoantibodies plus PSA has potential implications for classification of prostate cancer from non-malignant cases. J Transl Med. 2011 Apr 19;9:43.

Marks LS, Huang J. Words of wisdom. Re: copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Eur Urol. 2010 Apr;57(4):727-8.

Isbarn H, Pinthus JH, Marks LS, Montorsi F, Morales A, Morgentaler A, Schulman C. Testosterone and prostate cancer: revisiting old paradigms. Eur Urol. 2009 Jul;56(1):48-56. Epub 2009 Apr 8